More adverse factors occurred in those with intermediate-risk prostate cancer undergoing neoadjuvant androgen deprivation therapy than those who did not.
External beam radiation therapy (EBRT) with or without short-term neoadjuvant androgen deprivation therapy (STAD) elicited 15-year survival in patients with intermediate-risk prostate cancer (IRPC), according to a study presented in a poster session at the 2025 ASCO Genitourinary Cancer Symposium.1
Data from the trial revealed that at a median follow-up of 12.0 years and a maximum of 19.8 years, the 15-year prostate cancer–specific survival (PCSS) rate was 91% for patients with IRPC undergoing STAD plus EBRT and those receiving EBRT alone (P = .67). Additionally, the 15-year overall survival (OS) rate was 53% for those…